226 Users Online
Point-of-care Cancer Screening Market Segmented By Screening type such as Genetic Screening, Laboratory Screening, Imaging Screening, Biopsy Screening, Pre-Endoscopy Screening with Cancer Type such as Lung Cancer, Breast Cancer, Cervical Cancer, Blood Cancer, Kidney and Colorectal Cancer, Prostate Cancer, Others
Cancer is one of the leading causes of mortality for 1 in 7 individuals globally. It is globally acknowledged that early diagnosis and screening are of major importance for improving the likelihood of recovery. However, given the time-consuming, costly, and invasive nature of existing methods for cancer screening, patients often do not prefer these services.
Researchers are focused on developing reliable, non-invasive, and fast diagnostic tools that can be directly used by the local physicians for point-of-care cancer screening. Incorporation of various biomarkers into point-of-care cancer screening devices is expected to potentially reduce the strain experienced by various healthcare systems and hospitals.
Essentially, point-of-care cancer screening is capable of enhancing the well-being of patients and could further lead to a reduction in cancer-related deaths, globally. Point-of-care cancer screening tests are being miniaturized and simplified, for reducing the overall cost of equipment, materials, and personnel costs. The use of biosensor technologies and “lab-on-a-chip” has facilitated this change, making point-of-care cancer screening possible “on-site”.
Cancer impacts public health tremendously and the continuous growth of this impact is one of the primary factors driving the demand for point-of-care cancer screening during the forecast period. Increasing incidence of various cancer types across regions and high mortality rates due to cancer is also expected to fuel demand for point-of-care cancer screening.
Increasing programs on awareness and comprehensive approach by various organizations for the prevention and control of cancer is also expected to contribute to the growth of point-of-care cancer screening market during the forecast period.
Government-centered initiatives for point-of-care cancer screening, convenience of these screenings and cost effectiveness are also expected to boost demand for point-of-care cancer screening, globally. However, lack of awareness about point-of-care cancer screening in developing regions, stringent regulations regarding point-of-care cancer screening is expected to obstruct market growth for point-of-care cancer screening during the forecast period.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
| Based on screening type |
|
| Based on cancer type |
|
| Based on end use |
|
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionThe point-of-care cancer screening market is projected to witness a robust growth in the North America region owing it to the increasing incidence of various forms of cancer and huge number of developmental companies present for point-of-care cancer screening manufacturing in the region.
Asia-Pacific’s point-of-care cancer screening market and Europe’s market for Point-of-care cancer screening is also expected to grow at a significant rate during the forecast period due to growing awareness on the cost-effectiveness of point-of-care cancer screening tests. Increase in healthcare expenditure and improved healthcare infrastructure in also expected to propel market demand for point-of-care cancer screening in these regions.
MEA point-of-care cancer screening market is expected to witness decent growth owing it to the poor healthcare infrastructure and low awareness about point-of-care cancer screening.
Some of the market participants in the Global point-of-care cancer screening market identified across the value chain include Hologic Corporation, Abbott Laboratories, Qiagen N.V., and F Hoffmann-La Roche, BD, Quest Diagnostics, OncoHealth Corp, Danaher, NOVIGENIX SA, and Quidel Corporation.
Sales Team
Client Partner
